Veracyte Inc
Atidarymo kaina
SektoriusSveikatos priežiūra
48.29 2.16
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
46.6
Max
47.91
Pajamos | -20M 29M |
|---|---|
Pardavimai | -1.6M 139M |
P/E Sektoriaus vid. | 45.019 49.052 |
Pelnas, tenkantis vienai akcijai | 0.52 |
Pelno marža | 20.642 |
Darbuotojai | 755 |
EBITDA | -17M 29M |
Rekomendacijos | Pirkti |
|---|---|
12 mėnesių prognozė | +0.51% upside |
Kitas uždarbis | 2026-08-05 |
|---|
Rinkos kapitalizacija | 1.1B 3.8B |
|---|---|
Ankstesnė atidarymo kaina | 46.13 |
Ankstesnė uždarymo kaina | 48.29 |
Naujienos nuotaikos
By Acuity
50%
50%
146 / 342 reitingas Healthcare
Veracyte Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.